Research progress of application of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syn-drome
10.3969/j.issn.1008-0074.2015.01.26
- VernacularTitle:血小板糖蛋白 IIb/IIIa 受体拮抗剂在急性冠脉综合征应用研究的进展
- Author:
Jianbing ZHU
;
Junfeng ZHANG
- Publication Type:Journal Article
- Keywords:
Platelet glycoprotein GPIIb-IIIa complex;
Platelet aggregation inhibitors;
Acute coronary syndrome
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2015;24(1):88-91
- CountryChina
- Language:Chinese
-
Abstract:
Through occupying binding site of glycoprotein IIb/IIIa receptor,platelet glycoprotein IIb/IIIa inhibitor (GPI)inhibit the combination of fibrinogen and the receptor,then inhibit platelet aggregation.GPI is the most powerful anti-platelet drug and possesses application value in ACS now.This article made an overview on the newest research progress of safety and effectiveness of GPI in ACS.
